Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application

Journal of Immunotherapy

Volumn 31, Issue 5, 2008, Pages 506-519

  Möller, Ines ^a,b   Michel, Kathrin ^c   Frech, Nathalie ^a   Burger, Meike ^a   Pfeifer, Dietmar ^a   Frommolt, Peter ^d   Veelken, Hendrik ^a   Thomas Kaskel, Anna K ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

3 dioxygenase; Dendritic cell maturation; Gene expression analysis; Immunotherapy; Indoleamine 2; Poly(I:C); Prostaglandin E2

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; MELAN A; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; ALLOANTIGEN; CYTOKINE; HNA 4A ANTIGEN; HNA-4A ANTIGEN;

ARTICLE; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHENOTYPE; SECRETION;

CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; GENE EXPRESSION PROFILING; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; ISOANTIGENS; PHENOTYPE; POLY I-C; T-LYMPHOCYTES;

EID: 55249122934     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318177d9e5     Document Type: Article

References (48)

1. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23:445-449.
2. Hugues S, Fetler L, Bonifaz L, et al. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol. 2004;5:1235-1242.
3. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435-1440.
4. De Smedt T, Pajak B, Muraille E, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med. 1996;184:1413-1424.
5. Verdijk RM, Mutis T, Esendam B, et al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57-61.
6. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-5937.
7. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol. 2005;17:338-344.
8. Rieser C, Bock G, Klocker H, et al. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997; 186:1603-1608.
9. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196: 137-151.
10. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
11. Luft T, Jefford M, Luetjens P, et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002;100:1362-1372.
12. Scandella E, Men Y, Legler DF, et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood. 2004;103:1595-1601.
13. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005;106:2375-2381.
14. von Bergwelt-Baildon MS, Popov A, Saric T, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006;108:228-237.
15. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97: 3466-3469.
16. Harizi H, Juzan M, Pitard V, et al. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol. 2002;168: 2255-2263.
17. Spisek R, Bretaudeau L, Barbieux I, et al. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 2001;50:417-427.
18. H2 cell-promoting dendritic cells in vitro with diverse TH cell-polarizing signals. J Immunol. 2002;168:1704-1709.
19. Pedersen AE, Thorn M, Gad M, et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol. 2005;61:147-156.
20. Ten Brinke A, Karsten ML, Dieker MC, et al. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce TH1 polarization. Vaccine. 2007;25:7145-7152.
21. Zobywalski A, Javorovic M, Frankenberger B, et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007;5:18.
22. Krause P, Singer E, Darley PI, et al. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol. 2007;82:1106-1114.
23. Lanzavecchia A. Immunology. Licence to kill. Nature. 1998;393: 413-414.
24. Thomas-Kaskel AK, Portugal TG, Herchenbach D, et al. Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematol. 2007;117:226-235.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289-300.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
27. Daubener W, Wanagat N, Pilz K, et al. A new, simple, bioassay for human IFN-gamma. J Immunol Methods. 1994;168:39-47.
28. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776.
29. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol. 2005;3: 281-294.
30. di Carlo E, de Totero D, Piazza T, et al. Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother. 2007;56:1323-1334.
31. H2 cytokines in antigen-presenting cells. Scand J Immunol. 2004;60:233-237.
32. H2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol. 2005;83:525-535.
33. Saeki H, Moore AM, Brown MJ, et al. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol. 1999; 162:2472-2475.
34. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774.
35. Grufman P, Karre K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol. 2000;30: 1088-1093.
36. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84: 4008-4027.
37. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
38. Lehtonen A, Ahlfors H, Veckman V, et al. Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells. J Leukoc Biol. 2007;82:710-720.
39. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(suppl 4):A8-A22.
40. Rouas R, Lewalle P, El Ouriaghli F, et al. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol. 2004;16:767-773.
41. H1- polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother. 2005;28:480-487.
42. H cells. J Immunol. 1999;162:3231-3236.
43. Terness P, Chuang JJ, Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 2006;27: 68-73.
44. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190:705-715.
45. Legler DF, Krause P, Scandella E, et al. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol. 2006;176:966-973.
46. Alder J, Hahn-Zoric M, Andersson BA, et al. Interferon-gamma dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines. Vaccine. 2006;24:7087-7094.
47. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-290.
48. Wan Y, Lu L, Bramson JL, et al. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8(+) CTL in vivo. J Immunol. 2001;167:5027-5033.